Biblio
Nilotinib with or without cytarabine for Philadelphia positive acute lymphoblastic leukemia. Blood. 2024.
Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions. Curr Hematol Malig Rep. 2024.
. Using Measurable Residual Disease to Optimize Management of AML, ALL, and Chronic Myeloid Leukemia. Am Soc Clin Oncol Educ Book. 2023;43:e390010.
.